Who Makes Mounjaro? The Manufacturer, the Molecule, and the Story Behind It

Key Takeaways

• Mounjaro is made by Eli Lilly and Company, an Indianapolis-based pharmaceutical manufacturer founded in 1876.
• The active ingredient, tirzepatide, was discovered and developed in-house by Eli Lilly's research division through more than a decade of peptide engineering work.
• Mounjaro received FDA approval in May 2022 for adults with type 2 diabetes; the same molecule was later approved as Zepbound for chronic weight management in November 2023.
• Manufacturing for the U.S. market happens primarily at Lilly facilities in Indianapolis, Indiana; Concord, North Carolina; and Research Triangle Park, North Carolina, with peptide synthesis at a Branchburg, New Jersey site.
• Mounjaro is not produced by Novo Nordisk, Pfizer, or any other manufacturer. It is a single-source brand-name product protected by patent through approximately 2036 in the U.S.

Direct answer (40-60 words)

Mounjaro is manufactured by Eli Lilly and Company, an Indianapolis-based pharmaceutical company. Its active ingredient, tirzepatide, was discovered, developed, and is produced exclusively by Lilly. The drug was FDA-approved for type 2 diabetes in May 2022 and is currently protected by patent in the United States through roughly 2036.

Table of contents

1. The 30-second answer
2. About Eli Lilly and Company
3. How tirzepatide was developed
4. Where Mounjaro is manufactured
5. Mounjaro vs Zepbound: same molecule, different label
6. The Mounjaro vs Ozempic / Wegovy manufacturer split
7. Patent and exclusivity timeline
8. Compounded tirzepatide and the manufacturing distinction
9. How to verify your Mounjaro pen is genuine
10. FAQ
11. Sources
12. Footer disclaimers

About Eli Lilly and Company

Eli Lilly is an American pharmaceutical company headquartered at Lilly Corporate Center, 893 South Delaware Street, Indianapolis, Indiana. The company was founded in 1876 by Colonel Eli Lilly, a Civil War veteran and pharmaceutical chemist. As of 2026, the company employs roughly 47,000 people across more than 18 countries.

Lilly's historical product portfolio includes the first commercial insulin (Iletin, 1923), the first commercial fluoxetine (Prozac), and the cancer drug pemetrexed (Alimta). The company has been a major player in the diabetes and metabolic-disease space for over a century.

For Mounjaro specifically, Lilly is the:

• Discovery sponsor (the molecule was invented in-house by Lilly chemists)
• Patent holder (U.S. and international)
• Clinical trial sponsor (the SURPASS and SURMOUNT trial programs)
• Regulatory applicant (FDA, EMA, MHRA, PMDA)
• Manufacturer (peptide synthesis and pen assembly)
• Distributor and marketer

This vertical integration is standard for branded biologic and peptide drugs. Lilly is the only legitimate source of brand-name Mounjaro globally.

How tirzepatide was developed

Tirzepatide (the active ingredient in Mounjaro and Zepbound) is a 39-amino-acid peptide engineered from a glucose-dependent insulinotropic polypeptide (GIP) backbone with modifications that allow it to activate both GIP and GLP-1 receptors. It was first described in scientific literature in a 2020 publication in Molecular Metabolism by Lilly researchers Coskun, Sloop, and colleagues.

The development timeline:

• 2010s: Lilly research into dual incretin agonism. The hypothesis was that combining GIP and GLP-1 receptor activation in a single molecule would produce greater metabolic effects than either alone.
• 2017: First-in-human Phase 1 studies of LY3298176 (the internal Lilly compound code that became tirzepatide).
• 2018 to 2021: SURPASS Phase 3 trial program for type 2 diabetes (SURPASS-1 through SURPASS-5).
• May 2022: FDA approval for type 2 diabetes management. Brand name: Mounjaro.
• 2021 to 2023: SURMOUNT Phase 3 trial program for chronic weight management.
• November 2023: FDA approval for chronic weight management. Brand name: Zepbound.
• 2024 to 2026: Continued indication expansion, including obstructive sleep apnea (Zepbound) and ongoing investigation in other metabolic conditions.

The dual GLP-1/GIP mechanism was a meaningful pharmacologic innovation. Earlier GLP-1 agonists (semaglutide, liraglutide, dulaglutide) target only one receptor. The SURPASS-2 head-to-head trial showed tirzepatide produced about 1.5 to 2 percentage points greater A1C reduction and around 5 percentage points greater weight loss than semaglutide at the high doses (Frias et al., NEJM 2021).

Where Mounjaro is manufactured

Lilly produces Mounjaro through a multi-site supply chain. As of 2026, the principal U.S. manufacturing sites for Mounjaro and Zepbound are:

• Indianapolis, Indiana (multiple facilities). Headquarters site, includes pen assembly and packaging operations.
• Research Triangle Park, North Carolina. Active pharmaceutical ingredient (API) production.
• Concord, North Carolina. Sterile fill-finish operations and pen device assembly. This site received over $2 billion in expansion investment beginning in 2022.
• Branchburg, New Jersey. Peptide synthesis facility acquired by Lilly from Nexus Pharmaceuticals in 2023 to expand tirzepatide capacity.
• Lebanon, Indiana. A new $9 billion campus announced in 2024, scheduled to come online for tirzepatide manufacturing in 2026 and 2027.
• Limerick, Ireland. International manufacturing site supporting global supply.

Demand for tirzepatide has consistently exceeded Lilly's manufacturing capacity since launch. The company invested over $20 billion in expanded capacity between 2022 and 2026, but supply constraints have persisted intermittently throughout that period (FDA Drug Shortage list, 2023-2024 records).

Mounjaro vs Zepbound: same molecule, different label

Both Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same concentrations and in the same delivery device.

Why two brand names for one molecule? Because the FDA approves drugs by indication, and insurance plans cover them by indication. A patient with diabetes and obesity would typically get Mounjaro, where the diabetes coverage is strong and the weight loss is a beneficial side effect. A patient without diabetes who is being treated for obesity would get Zepbound. The split lets each brand carry the right marketing, labeling, and insurance pathway for its primary use.

The pens are not interchangeable from an insurance standpoint, but the medication inside is identical.

The Mounjaro vs Ozempic / Wegovy manufacturer split

A common point of confusion: Ozempic and Wegovy are made by a different company.

Eli Lilly and Novo Nordisk are the two dominant companies in the modern GLP-1 space. They are competitors. Lilly does not produce Ozempic or Wegovy, and Novo Nordisk does not produce Mounjaro or Zepbound.

If a website or marketplace claims to sell "Mounjaro by Novo Nordisk" or "Ozempic by Eli Lilly," that product is either mislabeled, counterfeit, or a different product entirely.

Patent and exclusivity timeline

Tirzepatide's patent protection in the United States runs through approximately 2036. Specific patent dates:

• Composition-of-matter patents: filed 2016 to 2018, with standard 20-year terms running through roughly 2036 to 2038
• Method-of-use patents: separate filings extending parts of exclusivity into the late 2030s
• Pediatric exclusivity extension: possible to add 6 months if Lilly conducts approved pediatric studies

Until those patents expire, generic tirzepatide cannot be legally marketed in the United States. Compounded tirzepatide is a separate regulatory category, governed by federal compounding rules rather than the new-drug pathway.

Compounded tirzepatide and the manufacturing distinction

During the 2023 to 2024 supply shortage of brand Mounjaro and Zepbound, the FDA placed tirzepatide on the resolved-shortage list. While on that list, state-licensed compounding pharmacies (503A and 503B) were permitted to compound tirzepatide for patients with valid prescriptions when clinically appropriate.

The FDA removed tirzepatide from the shortage list in late 2024. This restricted some compounding activity, though state 503A pharmacies retain the authority to compound tirzepatide for individual patients when clinical need is documented and proper prescriber oversight exists.

A few points to be clear about:

• Compounded tirzepatide is not made by Eli Lilly.
• It is not FDA-approved.
• It is prepared by state-licensed compounding pharmacies that source bulk peptide ingredient from FDA-registered API suppliers.
• It is not interchangeable with brand-name Mounjaro or Zepbound.
• Quality varies by pharmacy. Reputable 503A and 503B pharmacies test each batch for sterility, potency, and endotoxins under USP <797> standards.

When patients ask "who makes Mounjaro," the answer is Eli Lilly. When they ask "who makes compounded tirzepatide," the answer is a state-licensed compounding pharmacy, which varies by prescription. They are not the same product.

For more on the compounding pathway, see /articles/compounded-and-peptides/compounded-vs-brand-tirzepatide/ and /articles/compounded-and-peptides/503a-vs-503b-pharmacies/.

How to verify your Mounjaro pen is genuine

Counterfeit GLP-1 medications have appeared on gray-market websites since 2023. To verify authenticity of a Mounjaro pen:

1. Check the labeling. Genuine Mounjaro pens are labeled with "Eli Lilly and Company" as the manufacturer, a National Drug Code (NDC) number, and a lot/batch number.
2. Look at the pen device. Genuine Mounjaro pens are pre-filled, single-dose KwikPen-style devices in light teal (Mounjaro) or cobalt blue (Zepbound) with embossed Lilly branding.
3. Check the source. Mounjaro is dispensed in the United States only from licensed retail pharmacies and licensed mail-order pharmacies via valid prescription. Direct-to-consumer websites that sell brand Mounjaro without a U.S. pharmacy in the chain are likely selling counterfeits or unlicensed imports.
4. Verify the lot number. If you have any doubt, call Lilly's customer line at 1-800-LillyRx (1-800-545-5979) with the lot number printed on the pen.
5. Inspect the pen itself. Counterfeits often have spelling errors on the label, off-color packaging, missing batch information, or inconsistent fonts.

Compounded tirzepatide is not branded as Mounjaro. If a vial or syringe is labeled "compounded tirzepatide" rather than "Mounjaro," it is not the brand product, and that labeling is appropriate.

FAQ

Who makes Mounjaro? Mounjaro is made by Eli Lilly and Company, headquartered in Indianapolis, Indiana. Lilly discovered, developed, and exclusively manufactures tirzepatide, the active ingredient in Mounjaro and Zepbound.

Where is Mounjaro manufactured? Mounjaro is produced at multiple Eli Lilly facilities in the United States, including Indianapolis (Indiana), Concord and Research Triangle Park (North Carolina), Branchburg (New Jersey), and Lebanon (Indiana, coming online 2026 to 2027). International production includes a Limerick, Ireland facility.

Is Mounjaro made by Novo Nordisk? No. Mounjaro is made by Eli Lilly. Novo Nordisk makes Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza. The two companies are competitors in the GLP-1 space.

Is Mounjaro the same as Ozempic? No. Mounjaro is tirzepatide (a dual GLP-1/GIP receptor agonist) made by Eli Lilly. Ozempic is semaglutide (a single GLP-1 receptor agonist) made by Novo Nordisk. They have similar effects but different molecules and different manufacturers.

Is Mounjaro the same as Zepbound? The active ingredient is the same: tirzepatide. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management. Both are made by Eli Lilly. Pens are not interchangeable from an insurance perspective.

When was Mounjaro approved? The FDA approved Mounjaro for type 2 diabetes management on May 13, 2022. The same molecule was later approved as Zepbound for chronic weight management on November 8, 2023.

Who discovered tirzepatide? Tirzepatide was discovered and developed by Eli Lilly's internal research organization. The molecule was first described in a 2020 Molecular Metabolism publication by Coskun, Sloop, and colleagues at Lilly. Phase 1 human studies began in 2017.

Is there a generic Mounjaro? No. Tirzepatide is on patent in the United States through approximately 2036. No generic version is legally available in the U.S. market.

Who makes compounded tirzepatide? Compounded tirzepatide is not made by Eli Lilly. It is prepared by state-licensed compounding pharmacies (503A and 503B) for individual patients with valid prescriptions. Compounded tirzepatide is not FDA-approved and is not interchangeable with brand Mounjaro or Zepbound.

How do I know my Mounjaro pen is real? Authentic Mounjaro pens carry "Eli Lilly and Company" branding, an NDC number, a lot/batch code, and the distinctive light teal pen color. Buy from licensed U.S. pharmacies. Verify lot numbers with Lilly customer service at 1-800-545-5979 if you have doubts.

Why is Mounjaro hard to find sometimes? Demand for tirzepatide has consistently outpaced Lilly's manufacturing capacity since launch in 2022. The FDA placed tirzepatide on the drug shortage list during 2023 and 2024. Lilly has invested over $20 billion in capacity expansion, with new facilities coming online through 2026 and 2027.

Does Eli Lilly make insulin too? Yes. Lilly produced the first commercial insulin in 1923 (Iletin) and continues to make insulin products including Humalog, Humulin, and the rapid-acting Lyumjev. Lilly is one of three major insulin manufacturers globally.

Sources

1. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. Mol Metab. 2018;18:3-14.
2. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
4. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398:143-155.
5. FDA News Release. FDA approves novel, dual-targeted treatment for type 2 diabetes. May 13, 2022.
6. FDA News Release. FDA approves new medication for chronic weight management. November 8, 2023.
7. FDA Drug Shortage Database. Tirzepatide injection. Records 2023-2024.
8. Eli Lilly and Company. 2024 Annual Report and 10-K filing. SEC.gov.
9. FDA Mounjaro Prescribing Information. Eli Lilly and Company; revised 2024.
10. United States Pharmacopeia. USP <797> Pharmaceutical Compounding Sterile Preparations. 2023.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.